Tal Davidy, Iscka Yore, Tali Cukierman-Yaffe, Ramit Ravona-Springer, Abigail Livny, Orit H Lesman-Segev, Yossi Azuri, Owen Carmichael, Dimitrios Kapogiannis, Henrik Zetterberg, HungMo Lin, Mary Sano, Michal Schnaider Beeri
INTRODUCTION: We present the rationale and design of a double-blind placebo-controlled feasibility trial combining intranasal insulin (INI) with semaglutide, a GLP-1 receptor agonist, to improve cognition in older adults with metabolic syndrome (MetS) and mild cognitive impairment (MCI). Since both INI and dulaglutide have beneficial effects on the cerebrovascular disease (CVD), we anticipate that improved CVD will underlie the hypothesized cognitive benefits. METHODS: This 12-months trial will include 80 older adults aged >60 with MetS and MCI, randomized to 4 groups: INI/oral semaglutide, intranasal placebo/oral semaglutide, INI/oral placebo, and intranasal placebo/oral placebo...
December 28, 2023: Mechanisms of Ageing and Development